Needham & Company Reiterates a 'Buy' on Micromet (MITI); 2012 Preview
Tweet
Share
E-mailGet Alerts MITI Hot Sheet
Price: $0.03 --0%
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Micromet (NASDAQ: MITI) price target of $10.00.
Needham analyst says, "Micromet recently initiated a single-arm Phase 2 trial of blinatumomab designed for potential accelerated approval in adult relapsed/refractory Acute Lymphocytic Leukemia (r/r ALL). Results are expected early in 2013. A confirmatory Phase 3 randomized controlled trial is expected to begin in early 2012. We are favorably inclined based on encouraging data to date. Additional results from a dose-ranging Phase 2 trial of blinatumomab in adult r/r ALL patients at the 2011 ASH meeting demonstrated an impressive 68% CR/CRh rate, with a 75% rate at the dose and schedule selected for further development. Median survival has not been reached after a median follow-up period of 9.7 months. A 4 month median survival is typically seen in this difficult to treat population."
For an analyst ratings summary and ratings history on Micromet click here. For more ratings news on Micromet click here.
Shares of Micromet closed at $7.63 yesterday.
Needham analyst says, "Micromet recently initiated a single-arm Phase 2 trial of blinatumomab designed for potential accelerated approval in adult relapsed/refractory Acute Lymphocytic Leukemia (r/r ALL). Results are expected early in 2013. A confirmatory Phase 3 randomized controlled trial is expected to begin in early 2012. We are favorably inclined based on encouraging data to date. Additional results from a dose-ranging Phase 2 trial of blinatumomab in adult r/r ALL patients at the 2011 ASH meeting demonstrated an impressive 68% CR/CRh rate, with a 75% rate at the dose and schedule selected for further development. Median survival has not been reached after a median follow-up period of 9.7 months. A 4 month median survival is typically seen in this difficult to treat population."
For an analyst ratings summary and ratings history on Micromet click here. For more ratings news on Micromet click here.
Shares of Micromet closed at $7.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- York Space Systems (YSS) PT Lowered to $18 at Needham
- Nu Holdings (Nubank) (NU) PT Raised to $19 at Needham
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
